Geneos Wealth Management Inc. Increases Position in Insulet Corporation $PODD

Key Points

• Geneos Wealth Management Inc. increased its stake in Insulet Corporation by 17.9%, owning approximately 0.05% of the company valued at $9.3 million after purchasing additional shares.
• Multiple analysts have rated Insulet with a consensus rating of "Moderate Buy", with a price target averaging $335.12, reflecting strong confidence in the company's growth potential.
• Insulet reported a 32.9% year-over-year revenue increase for the last quarter, beating earnings expectations with $1.17 EPS, significantly higher than the consensus estimate of $0.92.

Geneos Wealth Management Inc. lifted its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 17.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 35,518 shares of the medical instruments supplier's stock after acquiring an additional 5,392 shares during the period. Geneos Wealth Management Inc. owned approximately 0.05% of Insulet worth $9,327,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after acquiring an additional 1,867 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Insulet by 2.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,909 shares of the medical instruments supplier's stock worth $5,228,000 after buying an additional 440 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock valued at $236,000 after acquiring an additional 412 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after acquiring an additional 874 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Insulet by 225.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after acquiring an additional 1,075 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PODD. Royal Bank Of Canada boosted their target price on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. The Goldman Sachs Group started coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Morgan Stanley restated an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Oppenheimer boosted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $335.12.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Stock Up 1.1%

Insulet stock traded up $3.84 during trading hours on Friday, hitting $341.78. 472,873 shares of the stock traded hands, compared to its average volume of 530,837. The firm's 50-day moving average price is $311.59 and its two-hundred day moving average price is $291.99. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The company has a market cap of $24.06 billion, a PE ratio of 103.88, a PEG ratio of 2.81 and a beta of 1.36. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.